<DOC>
	<DOCNO>NCT02157935</DOCNO>
	<brief_summary>Comparing efficacy Symbicort® pMDI Formoterol Turbuhaler reduce exacerbation patient Chronic Obstructive Pulmonary Disease ( COPD ) .</brief_summary>
	<brief_title>Comparing Efficacy Symbicort® pMDI Formoterol Turbuhaler Reducing Exacerbations Patients With Cronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>A Phase IIIB , 6-Month , Double-blind , Double-dummy , Randomized , Parallel-group , Multicenter Exacerbation Study Symbicort® pMDI 160/4.5 μg x 2 Actuations Twice-daily Compared Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily COPD Patients .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>3 . A current clinical diagnosis COPD COPD symptom 1 year , accord GOLD guideline . 4 . Current previous smoker smoke history equivalent 10 pack year ( 1 pack year = 20 cigarette smoke per day 1 year ) . 5 . Postbronchodilator FEV1/forced vital capacity ( FVC ) &lt; 0.7 ( 70 % ) FEV1 ≤70 % predict normal ( PN ) value . 6 . Documented use shortacting inhaled bronchodilator ( β2agonists anticholinergic ) rescue medication within 6 month prior study start . 7 . A score ≥2 modify medical research council ( MMRC ) dyspnea scale . 8 . Documented history ≥1 moderate severe COPD exacerbation ( ) require treatment systemic ( oral , IM , IV ) corticosteroid ( minimum 3 day course oral corticosteroid treatment single depot corticosteroid injection ) , hospitalization ( defined inpatient stay &gt; 24 hour stay observation area emergency department equivalent facility depend country healthcare system ) within 252 week Visit 1 ( i.e. , within 14 day prior Visit 1 ) . A history exacerbation treat exclusively antibiotic consider adequate . 1 . A history asthma 18 year age . 2 . Subjects significant unstable ischemic heart disease , arrhythmia , cardiomyopathy , heart failure ( include significant cor pulmonale ) , uncontrolled hypertension define Investigator , relevant cardiovascular disorder judge Investigator . 3 . Known homozygous alpha1 antitrypsin deficiency . 4 . Any significant disease disorder ( e.g. , gastrointestinal , liver , renal , neurological , musculoskeletal , endocrine , metabolic , malignant , psychiatric , major physical impairment ) , opinion Investigator , may either put subject risk participation study , influence result study , subject 's ability participate study . 5 . A history malignancy ( except basal cell carcinoma ) within past 5 year . 6 . Active tuberculosis , lung cancer , bronchiectasis , sarcoidosis , lung fibrosis , primary pulmonary hypertension , interstitial lung disease , active pulmonary disease . 7 . Subjects need addition alteration usual maintenance change formulation rescue therapy COPD due worsening symptom within 14 day prior Visit 1 Visit 3 . 8 . CXR ( frontal lateral ) suspicion pneumonia condition/abnormality require additional investigation/treatment , put subject risk participation study . 9 . Risk factor pneumonia : immune suppression ( HIV , lupus ) risk pneumonia ( e.g . neurological disorder affect control upper airway , Parkinson 's disease , myasthenia gravis , etc. ) . 10 . Pneumonia resolve within 14 day Visit 1 . 11 . Moderate severe COPD exacerbation resolve within 14 day prior Visit 1 moderate severe COPD exacerbation occur Visit 1 Visit 2 . 12 . Longterm oxygen therapy ( LTOT ) nocturnal oxygen therapy require great 12 hour day . 13 . Subjects currently intensive rehabilitation phase schedule begin new participation ( intensive rehabilitation phase ) pulmonary rehabilitation program study start new pulmonary rehabilitation program within 60 day Visit 1 . Subjects maintenance phase pulmonary rehabilitation program exclude . 14 . Treatment oral , parenteral , intraarticular corticosteroid within 4 week prior Visit 1 . 15 . Omalizumab monoclonal polyclonal antibody therapy take reason within 6 month prior Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>COPD , turbuhaler , pMDI</keyword>
</DOC>